Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
11
1
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil
Role: lead
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
Role: lead
The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）
Role: lead
A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.
Role: lead
A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients
Role: lead
Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients
Role: lead
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)
Role: lead
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)
Role: lead
Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin
Role: lead
A Study of the Efficacy and Safety of Supaglutide in Healthy Participants
Role: lead
A Study of Supaglutide in Chinese Type 2 Diabetes Patients
Role: lead
All 11 trials loaded